Back to Newsroom

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent (EP1962814) including claims to novel pharmaceutical formulations of sapacitabine. The European patent will provide exclusivity until December 2026 excluding any extensions. Equivalent patents have been granted in the United States (US 8,497,291 expiring in January 2030) and other countries.